Oscar Health, Inc. OSCR
Set alert
31.62 USD +0.62 +2.00%
As of Nov 3, 11:38 AM ET
30.82 Day range 31.91
10.69 52-week range 35.01
- YTD
- +120.04%
- 1 year
- +79.05%
- Open
- 30.87
- Prev close
- 31.00
- Mkt cap
- 9.76B
- Vol
- 976.73K
- Avg vol
- 5.32M
- EPS
- 1.29
- P/E
- 24.51
- Div yield
- 0.00%
More statistics
- Low
- 30.82
- High
- 31.91
- Forward P/E
- 13.96
- Beta
- 2.49
- Short ratio
- 3.35
- Inst. own
- 74.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 31.71
- 200-d avg
- 23.60
- 1y target
- 36.40
MAX chart
Events in this range
- Aug 6, 2025Earnings: -0.89; estimate -0.9; surprise 1.11%
- Nov 6, 2025Earnings: -0.53; estimate -0.55; surprise 3.64%
- Feb 10, 2026Earnings: -1.24; estimate -0.9214; surprise -34.58%
- May 6, 2026Earnings: 2.07; estimate 1.21; surprise 71.07%
- Aug 6, 2026Earnings: 1.1; estimate 0.403; surprise 172.95%
- Sep 17, 2026Rating: Baird · Neutral → Neutral
- Sep 17, 2026Rating: Barclays · Overweight → Overweight
- Sep 17, 2026Rating: Stephens & Co. · Equal-Weight → Equal-Weight
- Sep 17, 2026Rating: B of A Securities · Underperform → Underperform
- Sep 18, 2026Rating: Raymond James · Outperform → Outperform
- Oct 12, 2026Rating: UBS · Neutral → Neutral
- Nov 5, 2026Earnings: —; estimate -0.14382; surprise —%
Signals (110)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jul 27, 2026 | 3 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| RSI: Overbought | May 11, 2026 | 5 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| SMA: Bearish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
Newest 20 of 110.
Analyst view
Consensus: hold
Hold
Price target (mean) 36.40 +15.1% upside
Now 31.62
- Target (low)
- 27.00
- Target (mean)
- 36.40
- Target (high)
- 49.00
Ratings (0m) 11 3 buy · 7 hold · 1 sell
- Strong buy3
- Buy0
- Hold7
- Sell0
- Strong sell1
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17339 | -0.40 – 0.07 | -0.53 | +67.3% | 4.72B | +58.0% | 7 |
| Next quarter | -1.08 | -1.30 – -0.95 | -1.24 | +12.8% | 4.48B | +59.5% | 7 |
| Current year | 1.94 | 1.80 – 2.12 | -1.69 | +215.0% | 18.73B | +60.1% | 8 |
| Next year | 2.22 | 2.00 – 2.35 | 1.94 | +14.3% | 20.78B | +10.9% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | Maintained | Neutral | Neutral |
| Sep 18, 2026 | Raymond James | Maintained | Outperform | Outperform |
| Sep 17, 2026 | B of A Securities | Maintained | Underperform | Underperform |
| Sep 17, 2026 | Stephens & Co. | Reiterated | Equal-Weight | Equal-Weight |
| Sep 17, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Baird | Maintained | Neutral | Neutral |
| Aug 13, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | UBS | Maintained | Neutral | Neutral |
| Aug 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jun 10, 2026 | Barclays | Upgrade | Equal-Weight | Overweight |
| May 26, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | UBS | Maintained | Neutral | Neutral |
| May 7, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 7, 2026 | Baird | Maintained | Neutral | Neutral |
| May 6, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Apr 20, 2026 | Jefferies | Upgrade | Underperform | Hold |
| Jan 9, 2026 | UBS | Upgrade | Sell | Neutral |
| Jan 5, 2026 | Barclays | Upgrade | Underweight | Equal-Weight |
| Dec 11, 2025 | Stephens & Co. | Initiated | — | Equal-Weight |
| Nov 26, 2025 | Piper Sandler | Upgrade | Neutral | Overweight |
| Nov 13, 2025 | Wells Fargo | Maintained | Underweight | Underweight |
| Nov 10, 2025 | Barclays | Maintained | Underweight | Underweight |
| Nov 7, 2025 | UBS | Maintained | Sell | Sell |
| Oct 14, 2025 | Goldman Sachs | Initiated | — | Neutral |
| Oct 7, 2025 | Wells Fargo | Maintained | Underweight | Underweight |
| Aug 14, 2025 | Piper Sandler | Maintained | Neutral | Neutral |
| Jul 25, 2025 | Baird | Downgrade | Outperform | Neutral |
| Jul 23, 2025 | Barclays | Maintained | Underweight | Underweight |
| Jul 15, 2025 | UBS | Downgrade | Neutral | Sell |
| Jul 11, 2025 | Wells Fargo | Downgrade | Equal-Weight | Underweight |